Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$39.82 – $43.12
77% from low
Exchange
ARCX
ETF
Borrow rate
0.68%
Easy to borrow
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| LEMBiShares J.P. Morgan EM Local Currency Bond ETF | $42.34 | -0.20% | $421M | — |
| CEMBiShares J.P. Morgan EM Corporate Bond ETF | $45.42 | -0.50% | $429M | — |
| EEMSiShares MSCI Emerging Markets Small-Cap ETF | $74.73 | -1.52% | $401M | — |
| EMHYiShares J.P. Morgan EM High Yield Bond ETF | $40.45 | -0.53% | $590M | — |
| EWQiShares MSCI France ETF |
No company description on file.
No one on the platform currently holds LEMB.
No tracked institution reports a position in LEMB as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2025-12-19 | $1.0153 | 2025-12-24 |
| 2023-12-14 | $0.4916 | 2023-12-20 |
No one on the platform has traded LEMB yet.
| $44.92 |
| -1.11% |
| $382M |
| — |
| GVIPGoldman Sachs Hedge Industry VIP ETF | $185.22 | -1.84% | $583M | — |
| HYBBiShares BB Rated Corporate Bond ETF | $46.52 | -0.53% | $282M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$INMB $LEMB $BIIB Let's go InmuneBio!! https://claude.ai/public/artifacts/3dd6649c-e7bf-4f60-9771-28a79622d962 INMB INMB INMB
View on StockTwits ↗$INMB Massive Paradigm Shift in Alzheimer's! The new Cochrane Review (CD016297) just dealt a devastating blow to the anti-amyloid hypothesis. 🚫 Gold-standard data from 42 trials shows that drugs like $LEMB and $BIIB clear plaque but fail to deliver meaningful cognitive benefits, while carrying serious safety risks like brain swelling (ARIA). 🤯 The market narrative is crumbling. Enter $INMB. Their lead asset, XPro™, targets neuroinflammation (soluble TNF), not amyloid. Cochrane's expert recommendation is clear: "Future research... should focus on other treatments." 💡 INmune Bio is the necessary evolution that Cochrane is inadvertently calling for. Structurally de-risked and perfectly positioned with XPro™ moving into pivotal trials with a biomarker-enriched design. Time to look beyond the failed amyloid funnel-vision. Check out my full strategic analysis in the graphic below! 🚀 #Alzheimers #Biotech #Investing #Neuroscience #TheNewNarrative https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016297/full?highlightAbstract=alzheimer%7Calzheimer%27s%7Calzheim
View on StockTwits ↗$LEMB Current Stock Price: $42.38 Contracts to trade: $47.0 LEMB Feb 20 2026 Call Entry: $0.05 Exit: $0.07 ROI: 53% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗4/4: JPMorgan cuts emerging‑market FX view to market weight on overcrowding after year‑long rally | View: JPMorgan’s downgrade from overweight to market weight highlights overcrowded EM FX positioning, raising near‑term… $EEM $EMLC $LEMB $UUP
View on StockTwits ↗In the last month $LEMB has a been trading in a tight range between 35.96 and 36.86. https://www.chartmill.com/stock/quote/LEMB/technical-analysis?key=ff99ed94-5af8-40d0-8df1-5e78e6e31e41&utm_source=TA&utm_medium=stocktwits&utm_campaign=TA&utm_content=LEMB
View on StockTwits ↗$LEMB may break out. Our analyzer suggests a buy stop @37.15 with a stop @36.86 as a possible low risk setup.. https://www.chartmill.com/stock/quote/LEMB/technical-analysis?key=ff99ed94-5af8-40d0-8df1-5e78e6e31e41&utm_source=stocktwits&utm_medium=TA&utm_content=LEMB&utm_campaign=social_tracking
View on StockTwits ↗$LEMB - IShares JP maximum pain price is slips to -1.0 https://www.macroaxis.com/stock-options/LEMB/IShares-JP-Morgan?utm_source=dlvr.it&utm_medium=stocktwits
View on StockTwits ↗Emerging Markets Presents Healthy Fundamentals $EBND $ELD $LEMB https://talkmarkets.com/content/bonds/emerging-markets-presents-healthy-fundamentals?post=391792
View on StockTwits ↗$LEMB - Maximum pain price builds up to -1.0 for IShares JP https://www.macroaxis.com/stock-options/LEMB/IShares-JP-Morgan?utm_source=dlvr.it&utm_medium=stocktwits
View on StockTwits ↗$LEMB - Option Volatility signal: IShares JP pin risk is slipping https://www.macroaxis.com/stock-options/LEMB/IShares-JP-Morgan?utm_source=dlvr.it&utm_medium=stocktwits
View on StockTwits ↗$LEMB: The long and short term trends are both positive. This is looking good! https://www.chartmill.com/stock/analyzer/stock/LEMB?key=ff99ed94-5af8-40d0-8df1-5e78e6e31e41&utm_source=stocktwits&utm_medium=TA&utm_content=LEMB&utm_campaign=social_tracking
View on StockTwits ↗Whitcomb & Hess Inc.,has filed Form 13F for Q4 2022.Opened NEW positions in $CVX $LEMB $MUB $VGIT $VIOO
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.